CN116745300A - 作为血小板活化因子受体拮抗剂的环戊烷并噻吩甲酰胺衍生物 - Google Patents

作为血小板活化因子受体拮抗剂的环戊烷并噻吩甲酰胺衍生物 Download PDF

Info

Publication number
CN116745300A
CN116745300A CN202180076849.5A CN202180076849A CN116745300A CN 116745300 A CN116745300 A CN 116745300A CN 202180076849 A CN202180076849 A CN 202180076849A CN 116745300 A CN116745300 A CN 116745300A
Authority
CN
China
Prior art keywords
alkyl
group
optionally
optionally substituted
alkylene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180076849.5A
Other languages
English (en)
Chinese (zh)
Inventor
M·埃克哈特
M·K·威尔瓦赫
J·普雷斯特尔
F·孔特斯
L·托马斯
C·S·陶特曼
D·维登迈尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Original Assignee
Boehringer Ingelheim International GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International GmbH filed Critical Boehringer Ingelheim International GmbH
Priority to CN202311341729.0A priority Critical patent/CN117624188B/zh
Publication of CN116745300A publication Critical patent/CN116745300A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Hydrogenated Pyridines (AREA)
CN202180076849.5A 2020-11-16 2021-11-12 作为血小板活化因子受体拮抗剂的环戊烷并噻吩甲酰胺衍生物 Pending CN116745300A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202311341729.0A CN117624188B (zh) 2020-11-16 2021-11-12 作为血小板活化因子受体拮抗剂的环戊烷并噻吩甲酰胺衍生物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20207719.4 2020-11-16
EP20207719 2020-11-16
PCT/EP2021/081459 WO2022101377A1 (en) 2020-11-16 2021-11-12 Cyclopentathiophene carboxamide derivatives as platelet activating factor receptor antagonists

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202311341729.0A Division CN117624188B (zh) 2020-11-16 2021-11-12 作为血小板活化因子受体拮抗剂的环戊烷并噻吩甲酰胺衍生物

Publications (1)

Publication Number Publication Date
CN116745300A true CN116745300A (zh) 2023-09-12

Family

ID=73543025

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202180076849.5A Pending CN116745300A (zh) 2020-11-16 2021-11-12 作为血小板活化因子受体拮抗剂的环戊烷并噻吩甲酰胺衍生物
CN202311341729.0A Active CN117624188B (zh) 2020-11-16 2021-11-12 作为血小板活化因子受体拮抗剂的环戊烷并噻吩甲酰胺衍生物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202311341729.0A Active CN117624188B (zh) 2020-11-16 2021-11-12 作为血小板活化因子受体拮抗剂的环戊烷并噻吩甲酰胺衍生物

Country Status (20)

Country Link
US (2) US11766443B2 (cg-RX-API-DMAC7.html)
EP (1) EP4244229A1 (cg-RX-API-DMAC7.html)
JP (3) JP7465368B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230109692A (cg-RX-API-DMAC7.html)
CN (2) CN116745300A (cg-RX-API-DMAC7.html)
AR (1) AR124070A1 (cg-RX-API-DMAC7.html)
AU (1) AU2021379248A1 (cg-RX-API-DMAC7.html)
CA (1) CA3200710A1 (cg-RX-API-DMAC7.html)
CL (2) CL2023001361A1 (cg-RX-API-DMAC7.html)
CO (1) CO2023005894A2 (cg-RX-API-DMAC7.html)
CR (2) CR20230211A (cg-RX-API-DMAC7.html)
DO (1) DOP2023000090A (cg-RX-API-DMAC7.html)
EC (1) ECSP23036210A (cg-RX-API-DMAC7.html)
IL (1) IL302769A (cg-RX-API-DMAC7.html)
JO (1) JOP20230107A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023005678A (cg-RX-API-DMAC7.html)
PE (1) PE20231855A1 (cg-RX-API-DMAC7.html)
SA (1) SA523440809B1 (cg-RX-API-DMAC7.html)
TW (1) TWI913356B (cg-RX-API-DMAC7.html)
WO (1) WO2022101377A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119842821A (zh) * 2025-01-06 2025-04-18 华中科技大学 稳定表达血小板活化因子受体的细胞株、构建方法及应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3502392A1 (de) 1985-01-25 1986-07-31 Boehringer Ingelheim KG, 6507 Ingelheim Neue thieno-triazolo-1,4-diazepino-2- carbonsaeureamide, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen
DD265405A5 (de) * 1986-01-21 1989-03-01 Boehringer Ingelheim Kg,De Neue thieno-1,4-diazepine
PH30676A (en) 1986-07-22 1997-09-16 Boehringer Ingelhein Kg Hetrazepine compounds which have useful pharmaceutical utility
MC1999A1 (fr) * 1987-12-18 1990-01-26 Hoffmann La Roche Composes tricycliques
US4959361A (en) * 1987-12-18 1990-09-25 Hoffmann-La Roche Inc. Triazolo(4,3-A)(1,4)benzodiazepines and thieno (3,2-F)(1,2,4)triazolo(4,3-A)(1,4)diazepine compounds which have useful activity as platelet activating factor (PAF) antagonists
EP0368175A1 (de) 1988-11-06 1990-05-16 Boehringer Ingelheim Kg 3S,7S-3-(Morpholinocarbonyl)-5-(2-chlorphenyl)-7,10-dimethyl-3,4-dihydro-2H,7H-cyclopenta[4,5]thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin.
DE3909012A1 (de) 1989-03-18 1990-09-20 Boehringer Ingelheim Kg Verbessertes verfahren zur herstellung von enantiomerenreinen hetrazepinen
DE4010528A1 (de) 1990-04-02 1991-10-17 Boehringer Ingelheim Kg Praeparativ chromatographisches trennverfahren zur herstellung enantiomerenreiner hetrazepine
JP2959598B2 (ja) 1990-10-12 1999-10-06 吉富製薬株式会社 光学活性なチエノトリアゾロジアゼピン化合物
CN1033327C (zh) 1991-04-23 1996-11-20 东丽株式会社 三环三唑并衍生物的制造方法
DE4132763A1 (de) 1991-10-02 1993-04-08 Boehringer Ingelheim Kg Verbessertes verfahren zur herstellung von enantiomerenreinen saeureamiden hetrazepinoider struktur
FR2779652B1 (fr) 1998-06-15 2001-06-08 Sod Conseils Rech Applic Utilisation de diazepines pour la preparation de medicaments destines a traiter les etats pathologiques ou les maladies dans lesquels un des recepteurs de la somatostatine est implique
US20050032713A1 (en) * 2002-03-27 2005-02-10 Wurtman Richard J. Platelet-activating factor antagonists as analgesic, anti-inflammatory, uterine contraction inhibiting, and anti-tumor agents
US7749996B2 (en) 2006-11-20 2010-07-06 Alantos Pharmaceutical Holdings, Inc. Heterotricyclic metalloprotease inhibitors

Also Published As

Publication number Publication date
US20220160725A1 (en) 2022-05-26
CL2024000317A1 (es) 2024-07-12
AU2021379248A1 (en) 2023-06-22
TW202237620A (zh) 2022-10-01
CN117624188B (zh) 2026-08-07
JP7465368B2 (ja) 2024-04-10
CN117624188A (zh) 2024-03-01
PE20231855A1 (es) 2023-11-21
DOP2023000090A (es) 2023-06-15
JP7810743B2 (ja) 2026-02-03
CA3200710A1 (en) 2022-05-19
CO2023005894A2 (es) 2023-05-29
EP4244229A1 (en) 2023-09-20
JP2026090284A (ja) 2026-06-02
AU2021379248A9 (en) 2024-10-10
US11766443B2 (en) 2023-09-26
JP2023521200A (ja) 2023-05-23
ECSP23036210A (es) 2023-06-30
IL302769A (en) 2023-07-01
CR20230211A (es) 2023-07-13
SA523440809B1 (ar) 2024-10-08
WO2022101377A1 (en) 2022-05-19
US20230355638A1 (en) 2023-11-09
JOP20230107A1 (ar) 2023-05-16
KR20230109692A (ko) 2023-07-20
TWI913356B (zh) 2026-02-01
CL2023001361A1 (es) 2023-11-03
MX2023005678A (es) 2023-05-26
CR20260053A (es) 2026-03-24
JP2024099528A (ja) 2024-07-25
AR124070A1 (es) 2023-02-08

Similar Documents

Publication Publication Date Title
CN112041302B (zh) 作为lpa拮抗剂的吡唑o-连接的氨基甲酰基环己基酸
JP7299892B2 (ja) Lpaアンタゴニストとしてのシクロヘキシル酸ピラゾールアジン
TW201927765A (zh) 作為lpa拮抗劑之三唑n-連接之胺甲醯基環己基酸
CN113039181B (zh) 作为血浆激肽释放酶抑制剂的杂芳族甲酰胺衍生物
JP2021507898A (ja) Lpaアンタゴニストとしてのシクロヘキシル酸ピラゾールアゾール
CN112702998A (zh) 作为lpa拮抗剂的环庚酸
JP2025500886A (ja) 大環状btk阻害剤
WO2014101295A2 (zh) 一种詹纳斯激酶(JAKs)抑制活性的异恶唑衍生物
JP7703587B2 (ja) 血漿カリクレイン阻害剤としての複素芳香族カルボキシアミド誘導体
JP2023509001A (ja) Khk阻害効果を有する化合物
EP1301516A1 (en) Modulators of protein tyrosine phosphatases (ptpases)
JP7810743B2 (ja) 血小板活性化因子受容体アンタゴニストとしてのシクロペンタチオフェンカルボキサミド誘導体
WO2002004458A1 (en) Modulators of protein tyrosine phosphatases (ptpases)
CN112839711A (zh) 作为血浆激肽释放酶抑制剂的苯基四唑衍生物
EA048242B1 (ru) Циклопентатиофенкарбоксамидные производные в качестве антагонистов рецептора фактора активации тромбоцитов
JP2025501761A (ja) 血小板活性化因子受容体アンタゴニストとしてのシクロペンタチオフェンカルボキサミド誘導体
US20020099073A1 (en) Modulators of protein tyrosine phosphatases (PTPases)
CN121085992A (zh) 信号转导及转录激活蛋白6选择性降解剂化合物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination